Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000507-17-IT

Enrollment

Registered

2005-05-18

Start date

2004-06-10

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of unilateral spatial neglect and functional status in right brain damaged patients

Interventions

Product Name: Rivastigmine Product Code: NA Pharmaceutical Form: Capsule, hard INN or Proposed INN: Rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026